AR099071A1 - Antagonistas selectivos de nr2b - Google Patents
Antagonistas selectivos de nr2bInfo
- Publication number
- AR099071A1 AR099071A1 ARP150100065A ARP150100065A AR099071A1 AR 099071 A1 AR099071 A1 AR 099071A1 AR P150100065 A ARP150100065 A AR P150100065A AR P150100065 A ARP150100065 A AR P150100065A AR 099071 A1 AR099071 A1 AR 099071A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- halo
- alkyl
- compounds
- substituents selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos, incluyendo sus sales, así como composiciones y métodos de uso de los compuestos. Los compuestos son ligandos del receptor NR2B y pueden ser útiles para el tratamiento de diversos trastornos del sistema nervioso central. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) donde: Ar¹ es fenilo o indanilo y está sustituido con 0 - 3 sustituyentes seleccionados de ciano, halo, alquilo, haloalquilo y haloalcoxi; Ar² es fenilo sustituido con 1 sustituyente de OH y también sustituido con 0 - 3 sustituyentes seleccionados de ciano, halo, alquilo, haloalquilo y haloalcoxi; X es un enlace o alquileno C₁₋₃; n es 1 ó 2; y el anillo A es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, homopiperidinilo u homopiperazinilo y está sustituido con 0 - 4 sustituyentes seleccionados de halo, alquilo, hidroxi o alcoxi; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925363P | 2014-01-09 | 2014-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099071A1 true AR099071A1 (es) | 2016-06-29 |
Family
ID=52463126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100065A AR099071A1 (es) | 2014-01-09 | 2015-01-09 | Antagonistas selectivos de nr2b |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US9221796B2 (es) |
| EP (1) | EP3092224B1 (es) |
| JP (1) | JP6543259B2 (es) |
| KR (1) | KR102311518B1 (es) |
| CN (1) | CN106061961B (es) |
| AR (1) | AR099071A1 (es) |
| AU (1) | AU2015205001A1 (es) |
| CA (1) | CA2936293A1 (es) |
| CL (1) | CL2016001763A1 (es) |
| DK (1) | DK3092224T3 (es) |
| EA (1) | EA201691413A1 (es) |
| ES (1) | ES2693250T3 (es) |
| HR (1) | HRP20181585T1 (es) |
| HU (1) | HUE041986T2 (es) |
| IL (1) | IL246599A0 (es) |
| LT (1) | LT3092224T (es) |
| MX (1) | MX2016008898A (es) |
| PE (1) | PE20160933A1 (es) |
| PL (1) | PL3092224T3 (es) |
| PT (1) | PT3092224T (es) |
| RS (1) | RS57830B1 (es) |
| SG (1) | SG11201605618WA (es) |
| SI (1) | SI3092224T1 (es) |
| TR (1) | TR201815579T4 (es) |
| TW (1) | TWI640515B (es) |
| UY (1) | UY35947A (es) |
| WO (1) | WO2015105772A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| WO2017066368A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| CN108137543B (zh) | 2015-10-14 | 2021-11-23 | 百时美施贵宝公司 | 选择性nr2b拮抗剂 |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
| US10781172B2 (en) | 2018-06-21 | 2020-09-22 | Northwestern University | Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744448B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| WO2000063173A1 (en) | 1999-04-14 | 2000-10-26 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted piperidines |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| KR20020093950A (ko) * | 2000-04-26 | 2002-12-16 | 워너-램버트 캄파니 | 아형 선택적인 ｎｍｄａ 수용체 길항제로서의시클로헥실아민 유도체 |
| WO2003035641A1 (fr) | 2001-10-22 | 2003-05-01 | Shionogi & Co., Ltd. | Nouveau derive carbamoyl-pyrrolidone |
| SI1648882T1 (sl) | 2003-06-04 | 2009-02-28 | Merck & Co Inc | 3-fluoro-piperidini kot nmda/nr2b antagonisti |
| JP2007508288A (ja) | 2003-10-08 | 2007-04-05 | ファイザー株式会社 | 縮合ラクタム化合物 |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| MX2009014216A (es) | 2007-06-29 | 2010-07-05 | Univ Emory | Antagonistas del receptor nmda para neuroproteccion. |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2015
- 2015-01-05 US US14/589,205 patent/US9221796B2/en active Active
- 2015-01-06 EP EP15703328.3A patent/EP3092224B1/en active Active
- 2015-01-06 WO PCT/US2015/010262 patent/WO2015105772A1/en active Application Filing
- 2015-01-06 CN CN201580012735.9A patent/CN106061961B/zh active Active
- 2015-01-06 EA EA201691413A patent/EA201691413A1/ru unknown
- 2015-01-06 SI SI201530408T patent/SI3092224T1/sl unknown
- 2015-01-06 MX MX2016008898A patent/MX2016008898A/es unknown
- 2015-01-06 HU HUE15703328A patent/HUE041986T2/hu unknown
- 2015-01-06 PT PT15703328T patent/PT3092224T/pt unknown
- 2015-01-06 PL PL15703328T patent/PL3092224T3/pl unknown
- 2015-01-06 AU AU2015205001A patent/AU2015205001A1/en not_active Abandoned
- 2015-01-06 CA CA2936293A patent/CA2936293A1/en not_active Abandoned
- 2015-01-06 TR TR2018/15579T patent/TR201815579T4/tr unknown
- 2015-01-06 JP JP2016545819A patent/JP6543259B2/ja not_active Expired - Fee Related
- 2015-01-06 ES ES15703328.3T patent/ES2693250T3/es active Active
- 2015-01-06 LT LTEP15703328.3T patent/LT3092224T/lt unknown
- 2015-01-06 DK DK15703328.3T patent/DK3092224T3/en active
- 2015-01-06 KR KR1020167021356A patent/KR102311518B1/ko active IP Right Grant
- 2015-01-06 RS RS20181296A patent/RS57830B1/sr unknown
- 2015-01-06 SG SG11201605618WA patent/SG11201605618WA/en unknown
- 2015-01-06 PE PE2016001107A patent/PE20160933A1/es not_active Application Discontinuation
- 2015-01-08 TW TW104100592A patent/TWI640515B/zh not_active IP Right Cessation
- 2015-01-09 AR ARP150100065A patent/AR099071A1/es unknown
- 2015-01-09 UY UY0001035947A patent/UY35947A/es unknown
- 2015-10-13 US US14/882,041 patent/US20160081995A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246599A patent/IL246599A0/en unknown
- 2016-07-08 CL CL2016001763A patent/CL2016001763A1/es unknown
-
2017
- 2017-05-25 US US15/604,904 patent/US20170258777A1/en not_active Abandoned
- 2017-09-15 US US15/706,172 patent/US20180000807A1/en not_active Abandoned
- 2017-12-19 US US15/846,672 patent/US20180110766A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,067 patent/US20180250283A1/en not_active Abandoned
- 2018-10-03 HR HRP20181585TT patent/HRP20181585T1/hr unknown
- 2018-12-19 US US16/225,850 patent/US20190117638A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,831 patent/US20190314358A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,114 patent/US20200163949A1/en not_active Abandoned
- 2020-09-04 US US17/012,781 patent/US20210121453A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| PH12015501934B1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| CL2018003474A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| PE20181145A1 (es) | Compuestos de piridina | |
| ECSP16067303A (es) | Heteroarilos y usos de estos | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| TN2018000424A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX2021015102A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| PH12016500643A1 (en) | New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl | |
| NZ718055A (en) | Substituted pyrimidine bmi-1 inhibitors | |
| ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
| EA201891615A1 (ru) | Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора | |
| AR099071A1 (es) | Antagonistas selectivos de nr2b | |
| MX2016007128A (es) | Compuestos del receptor 6 de quimiocina (ccr6). | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
| DOP2020000118A (es) | Proceso para la preparación de derivados de quinolina | |
| CR20110405A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
| TH170304A (th) | ควินาโซลิน-thf-เอมีนที่เป็นตัวยับยั้ง pde1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |